Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2023-10-31 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于子公司撤回布洛芬注射液药品注册申请的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the withdrawal of a drug registration application by a subsidiary of the company. It includes details about the drug, regulatory approval status, and the company's decision to withdraw the application. There are no financial statements, earnings data, or detailed financial analysis. The document is a regulatory announcement about a specific corporate action related to product registration, not a financial report or meeting material. It fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2023-10-31 Chinese
公司章程（2023年10月）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of 福安药业（集团）股份有限公司, which is a detailed corporate governance document outlining the company's organizational structure, shareholder rights, board responsibilities, and other governance matters. It includes chapters on general provisions, business scope, shares issuance and transfer, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, financial accounting system, profit distribution, audit, notices and announcements, mergers, amendments to the articles, and supplementary provisions. The content is legal and governance-focused, not a financial report, earnings release, or meeting minutes. It is a governance document that defines the internal rules and structure of the company. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content confirm it is the full governance document, not just an announcement or summary.
2023-10-25 Chinese
章程修正案（2023年10月）
Governance Information Classification · 100% confidence The document is titled "福安药业（集团）股份有限公司 章程修正案" which translates to "Fuan Pharmaceutical (Group) Co., Ltd. Articles of Association Amendment." The content consists of detailed amendments to the company's articles of association, including changes to shareholder rights, board responsibilities, meeting procedures, and governance structures. It references the company's board meeting date and the need for shareholder approval. There is no financial data, earnings information, or audit content. The document is a formal governance document detailing internal company rules and board structure changes. Therefore, it fits the category of Governance Information (CGR). The document length is sufficient and contains substantive content, not just an announcement or notice, so it is not an RPA or RNS.
2023-10-25 Chinese
董事会审计委员会工作细则（2023年10月）
Governance Information Classification · 95% confidence The document is titled "董事会审计委员会工作细则" which translates to "Board Audit Committee Working Rules". It details the composition, responsibilities, meeting procedures, and operational rules of the audit committee of the company's board. There is no financial data, no report of financial results, no announcement of voting results, no legal proceedings, no capital changes, no earnings release, no management discussion, or any other report type. It is a governance document outlining internal rules and governance practices related to the audit committee. Therefore, it fits best under Governance Information (CGR). The document length is 5431 characters, which is sufficient for a detailed governance document. No indication that this is an announcement or a certification. Hence, the classification is CGR with high confidence.
2023-10-25 Chinese
董事会薪酬与考核委员会工作细则（2023年10月）
Governance Information Classification · 95% confidence The document is titled as the "Board of Directors Remuneration and Assessment Committee Working Rules" of a company. It details the structure, responsibilities, meeting procedures, and operational rules of the remuneration and assessment committee under the board of directors. It does not contain financial statements, earnings data, or any report of financial performance. Instead, it focuses on governance aspects related to board committees and their remuneration policies. This aligns with the definition of Governance Information (CGR), which covers internal rules, board structure, and governance practices. The document length is sufficient and it is not an announcement or a brief notice, but a detailed governance document. Therefore, the appropriate classification is CGR with high confidence.
2023-10-25 Chinese
董事会提名委员会工作细则（2023年10月）
Governance Information Classification · 95% confidence The document is titled as the "Board of Directors Nomination Committee Working Rules" for a company, detailing the structure, responsibilities, meeting procedures, and governance related to the nomination committee of the board. It focuses on internal governance rules, committee composition, meeting protocols, and duties related to board nominations and management appointments. There is no financial data, earnings information, audit results, or regulatory filings. The content is about governance practices and internal board committee rules, which aligns with Governance Information filings. The document length is over 6000 characters, indicating it is a substantive governance document, not a brief announcement or notice.
2023-10-25 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.